Acquired Company

Pathos AI completed its acquisition of Rain Oncology Inc. for $1.16 per share in cash plus one contingent value right, with the transaction closing on January 26, 2024.

Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology. It plans to develop improvements on existing rainfall generation technologies by introducing robust measurement tools, including software monitoring technology, machine learning, rain gauges, and weather stations. The company was founded in 2022 and is headquartered in Naples, Florida. Show more

4851 Tamiami Trail N, Naples, FL, 34103, United States

https://rainwatertech.com

Pollution & Treatment Controls

Industrials

Start AI Chat

Market Cap

20.55M

52 Wk Range

$1.75 - $9.58

Previous Close

$2.51

Open

$2.73

Volume

11,052

Day Range

$2.52 - $2.75

Enterprise Value

44.05M

Cash

236.7K

Avg Qtr Burn

-234K

Insider Ownership

73.61%

Institutional Own.

12.48%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (RAIN-32) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.